Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  COMPANY NEWS
Company News      
Zydus Lifesciences Ltd.
Change Company   
BSE Code 532321
ISIN Demat INE010B01027
Book Value 218.02
NSE Code ZYDUSLIFE
Dividend Yield % 1.23
Market Cap 902189.40
P/E 19.40
EPS 46.23
Face Value 1  
21-Mar-2026 Zydus Lifesciences launches Semaglutide Injection
21-Mar-2026 Zydus Lifesciences informs about press release
19-Mar-2026 Zydus Lifesciences informs about press release
18-Mar-2026 Zydus Lifesciences enters into licensing and supp...
18-Mar-2026 Zydus Lifesciences informs about press release
17-Mar-2026 Zydus Lifesciences, Lupin sign licensing agreemen...
17-Mar-2026 Zydus Lifesciences’ arm inks pact with PRG S&T to...
17-Mar-2026 Zydus Lifesciences gains as its arm inks pact wit...
16-Mar-2026 Zydus Lifesciences’ Desidustat tablets secure app...
13-Mar-2026 Zydus Lifesciences gets final nod for Cevimeline ...
12-Mar-2026 Zydus Lifesciences to launch continuous Glucose M...
28-Feb-2026 Zydus Lifesciences gets USFDA’s approval for Iver...
28-Feb-2026 Zydus Lifesciences submits press release
26-Feb-2026 Zydus Lifesciences to launch Semaglutide injectio...
26-Feb-2026 Zydus Lifesciences climbs on planning to launch S...
Page 1 of 5
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Smart ODR Portal | Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst | UPI QR CODE
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.